Jaguar Health to Discuss Orphan Disease Efforts in Upcoming Fireside Chat

Jaguar Health, Inc. announced the participation of its founder, Lisa Conte, in a virtual fireside chat on June 10, 2025, hosted by Lytham Partners. This talk aims to shed light on Jaguar's advancements in orphan disease development programs. Scheduled for 9:00 AM Eastern, the session is part of Lytham Partners' Spring 2025 Spotlight Series and will be available online.

Jaguar Health, a pharmaceutical company, focuses on plant-derived remedies for gastrointestinal issues. Their significant product, crofelemer, is FDA-approved under the brand Mytesi® for treating noninfectious diarrhea in adults with HIV/AIDS. The company's affiliate, Napo Pharmaceuticals, specializes in developing solutions for neglected gastrointestinal symptoms.

Napo Therapeutics, an Italian branch established in Milan, focuses on expanding crofelemer's reach in Europe, particularly for rare diseases. Moreover, Magdalena Biosciences, a joint venture with Filament Health Corp., targets mental health treatments through plant-based medications.